XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.2
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders of BridgeBio, because including them would have been antidilutive:

 

 

As of June 30,

 

 

2025

 

 

2024

 

Unvested RSUs

 

11,852,773

 

 

 

10,554,840

 

Unvested performance-based RSUs

 

194,943

 

 

 

3,326

 

Unvested market-based RSUs

 

375,000

 

 

 

375,000

 

Common stock options issued and outstanding

 

12,199,613

 

 

 

12,677,357

 

Estimated shares issuable under performance-based milestone
  compensation arrangements

 

1,681,209

 

 

 

3,811,055

 

Estimated shares issuable under the ESPP

 

112,977

 

 

 

106,012

 

Assumed conversion of 2027 Notes

 

12,878,305

 

 

 

12,878,305

 

Assumed conversion of 2029 Notes

 

7,702,988

 

 

 

7,702,988

 

Assumed conversion of 2031 Notes

 

11,544,448

 

 

 

 

 

58,542,256

 

 

 

48,108,883